Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Gini F. Fleming

This author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.

Honoraria: Curio Science, Physicans' Education Resource

Research Funding: Corcept Therapeutics (Inst), AbbVie (Inst), Iovance Biotherapeutics (Inst), Syros Pharmaceuticals (Inst), Sermonix Pharmaceuticals (Inst), Compugen (Inst), Plexxikon (Inst), Roche (Inst), GlaxoSmithKline (Inst), Celldex (Inst), AstraZeneca (Inst), Molecular Templates (Inst), CytomX Therapeutics (Inst), Astellas Pharma (Inst), K-Group Beta (Inst), Pfizer (Inst)

Other Relationship: DSI (Inst), Merck (Inst), Caris Life Sciences (Inst), Eisai (Inst), AstraZeneca (Inst)

Uncompensated Relationships: AbbVie

Eva M. Ciruelos

Consulting or Advisory Role: Roche, Pfizer, AstraZeneca, Novartis, Lilly, MSD Oncology, Daiichi Sankyo/Astra Zeneca, Novartis, Gilead Sciences, Seattle Genetics

Speakers' Bureau: Lilly, Roche, Daiichi Sankyo/Astra Zeneca, Novartis

Travel, Accommodations, Expenses: Roche, Pfizer

Hervé R. Bonnefoi

Consulting or Advisory Role: AstraZeneca/Daiichi Sankyo

Research Funding: Bayer (Inst)

Travel, Accommodations, Expenses: Pfizer, AstraZeneca/Daiichi Sankyo

Meritxell Bellet

Consulting or Advisory Role: Pfizer, Lilly, Novartis

Speakers' Bureau: Lilly, Pfizer, Novartis

Miguel A. Climent

Honoraria: Roche, Janssen, Astellas Pharma, Sanofi, Bayer, Bristol Myers Squibb, Merck, Pfizer, Novartis, Ipsen, Pierre Fabre, EUSA Pharma, MSD Oncology, AstraZeneca, Eisai Europe

Consulting or Advisory Role: Roche/Genentech, Bayer, Bristol Myers Squibb, Merck, Pfizer, Celgene, Eisai, Janssen-Cilag, Sanofi, EUSA Pharma, Astellas Pharma, Janssen Oncology, MSD Oncology

Travel, Accommodations, Expenses: Roche, Merck, Janssen, Ipsen, Pfizer

Silvana Martino

Consulting or Advisory Role: Merck, MorphoSys, Lilly, GlaxoSmithKline, Steba Biotech, Blue Print, Secura Bio, Pro Ed, TG Therapeutics, BeiGene, Secura Bio, 3D Communications

Begoña Bermejo

Consulting or Advisory Role: AstraZeneca/Daiichi Sankyo

Speakers' Bureau: Roche, MSD Oncology, Novartis/Pfizer, AstraZeneca/Daiichi Sankyo

Travel, Accommodations, Expenses: AstraZeneca

Harold J. Burstein

This author is a Consulting Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.

Charles E. Geyer

Consulting or Advisory Role: Exact Sciences

Research Funding: Genentech/Roche (Inst), AstraZeneca (Inst), Daiichi Sankyo/Astra Zeneca (Inst), AbbVie (Inst)

Travel, Accommodations, Expenses: AbbVie, Genentech/Roche, Daiichi-Sankyo, AstraZeneca

Barbara A. Walley

Stock and Other Ownership Interests: Pfizer (I)

Robert E. Coleman

Stock and Other Ownership Interests: Inbiomotion

Honoraria: AstraZeneca, Amgen, BeiGene

Consulting or Advisory Role: Sanofi

Research Funding: Bayer (Inst)

Expert Testimony: Amgen

Other Relationship: ACE Oncology

Fanny Le Du

Honoraria: Lilly, Novartis, Amgen

Consulting or Advisory Role: Pfizer, Lilly, Daiichi Sankyo/Astra Zeneca, Seagan, Novartis, Roche, Sandoz

Travel, Accommodations, Expenses: Daiichi Sankyo/Astra Zeneca, Lilly, Seagan, Novartis, Pfizer, Pierre Fabre

Sibylle Loibl

Consulting or Advisory Role: Pfizer (Inst), Roche (Inst), Novartis (Inst), Seattle Genetics (Inst), Celgene (Inst), Lilly (Inst), AstraZeneca/MedImmune (Inst), Bristol Myers Squibb (Inst), Merck KGaA (Inst), AbbVie (Inst), Amgen (Inst), Daiichi Sankyo (Inst), Pierre Fabre (Inst), Immunomedics (Inst), GlaxoSmithKline (Inst), EirGenix (Inst), Eisai Europe (Inst), Relay Therapeutics (Inst), Sanofi (Inst)

Speakers' Bureau: AstraZeneca (Inst), Daiichi Sankyo Europe GmbH (Inst), Novartis (Inst), Pfizer (Inst), Roche (Inst), Gilead Sciences (Inst)

Research Funding: AbbVie (Inst), AstraZeneca (Inst), Celgene (Inst), Novartis (Inst), Pfizer (Inst), Roche (Inst), Daiichi Sankyo (Inst), Gilead Sciences (Inst), MolecularHealth (Inst)

Patents, Royalties, Other Intellectual Property: Patent Pending EP14153692.0 (Inst), Patent Pending EP21152186.9 (Inst), Patent Issued EP15702464.7 (Inst), Patent Pending EP19808852.8 (Inst), Digital Ki67 Evaluator, VM Scope GmbH (Inst)

Eric P. Winer

Honoraria: Genentech/Roche, Genomic Health

Consulting or Advisory Role: Leap Therapeutics, Jounce Therapeutics, GlaxoSmithKline, Carrick Therapeutics, Genentech/Roche

Research Funding: Genentech (Inst)

Other Relationship: InfiniteMD

Sherene Loi

Consulting or Advisory Role: Roche/Genentech (Inst), Aduro Biotech (Inst), Novartis (Inst), G1 Therapeutics (Inst), PUMA Biotechnology (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst), Seattle Genetics (Inst), BMS (Inst), Silverback Therapeutics (Inst), Pfizer (Inst), Gilead Sciences (Inst), Daiichi Sankyo/Lilly (Inst), Tallac Therapeutics (Inst)

Research Funding: Roche/Genentech (Inst), Novartis (Inst), Merck (Inst), Puma Biotechnology (Inst), Bristol Myers Squibb (Inst), Seattle Genetics (Inst), AstraZeneca (Inst), Nektar (Inst), Lilly (Inst)

Other Relationship: Roche Medical writing support

Marco Colleoni

Research Funding: Roche (Inst)

Alan S. Coates

Stock and Other Ownership Interests: Avita Medical Inc, CSL Limited, Ramsay Health Care, Resmed

Richard D. Gelber

Research Funding: AstraZeneca (Inst), Novartis (Inst), Roche (Inst), Merck (Inst)

Meredith M. Regan

Honoraria: Bristol Myers Squibb, WebMD

Consulting or Advisory Role: Ipsen (Inst), Tolmar, Bristol Myers Squibb, Debiopharm Group (Inst)

Research Funding: Pfizer (Inst), Ipsen (Inst), Novartis (Inst), Merck (Inst), AstraZeneca (Inst), Pierre Fabre (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Roche (Inst), TerSera (Inst), Debiopharm Group (Inst)

No other potential conflicts of interest were reported.